Innate Pharma Sa (IPHA) Return on Investment ROI from the fourth quarter of 2025 to fourth quarter of 2024 and for the year 2025, average high and low, overall ranking from Dec 31 2025 to Dec 31 2024 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Innate Pharma Sa  (NASDAQ: IPHA)


Innate Pharma Sa's ROI from its fourth quarter of 2025 to the fourth quarter of 2024 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Innate Pharma Sa's ROI in the fourth quarter of 2025?
Due to the stockholders deficit and subsequent negative measured investments, it was not possible to calculate Innate Pharma Sa's return on investment (ROI) in its fourth quarter of 2025

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Dec 31 2025)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Dec 31 2024)
IV. Quarter
Y / Y Investment Change TTM - - - -97 % -85.46 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions -24 -24 -24 -24 10
Return On Investment (TTM) - - - - -543.16 %
IPHA's Overall Ranking # 5132 # 0 # # #
Seq. Investment Change TTM - - - -83.66 % -58.99 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -55 -55 -55 -55 -55

IPHA Company Profile >> Back to IPHA Roi Comparisons >> See Annual IPHA Return On Investment



Return On Investment IPHA's Ranking
Within: No.
Industry # 147
Sector # 965
Overall # 5132

Return On Investment Statistics
High Average Low
-8.65 %
-375.71 %
-1989.36 %
(Dec 31 2023)   (Dec 31 2025)







Financial Statements
Innate Pharma Sa's IV. Quarter Investments $ -24 Millions IPHA's Balance sheet
Innate Pharma Sa's IV. Quarter Income $ -55 Millions Quarterly IPHA's Income Statement
IPHA's Income by Division See IPHA's Income by Division


IPHA Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions -24 10 69 70 210
Y / Y Investment Growth - -85.19 % -2.24 % -66.46 % -28.38 %
Net Income in Millions -55 -55 -8 -65 -59
Y / Y Net Income Growth - - - - -
Annual Return On Investment - -543.16 % -12.31 % -92.35 % -28.15 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Biotechnology & Pharmaceuticals Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
IPHA's Roi Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for IPHA's Competitors
Subscribers only: Roi for Innate Pharma Sa's Suppliers
Subscribers only: Return On Investment for IPHA's Customers

Other Ratios
IPHA's Roa IPHA's Inventory Turnover Ratio IPHA's Growth Rates IPHA's Dividend Statistics
IPHA's Profitability Ratios IPHA's Asset Turnover Ratio IPHA's Dividend Growth
IPHA's Roe IPHA's Valuation Ratios IPHA's Financial Strength Ratios IPHA's Dividend Payout Ratio



Companies with similar Return On Investment at Dec 31 2025, within Healthcare Sector ROI
Glucotrack Inc   372.04 %
Elutia Inc   358.27 %
Oncotelic Therapeutics Inc   252.91 %
Atara Biotherapeutics Inc   242.55 %
Traws Pharma inc   234.73 %
Scisparc Ltd  234.01 %
Petros Pharmaceuticals inc   233.39 %
Omada Health Inc   200.69 %
Interpace Biosciences Inc   198.59 %
Rigel Pharmaceuticals Inc  185.38 %
Icecure Medical Ltd  166.12 %
Silexion Therapeutics Corp  142.64 %
Heartflow Inc   142.09 %
Capforce Inc   140.91 %
Check Cap Ltd  120.45 %
Coherus Oncology inc   119.44 %
Kyntra Bio Inc   118.89 %
Lifemd Inc   105.75 %
Biocryst Pharmaceuticals Inc   88.36 %
Advanced Biomed Inc.  84.64 %
Earth Science Tech Inc   78.43 %
Exelixis Inc   71.31 %
Entera Bio Ltd   63.91 %
Tg Therapeutics Inc   63.77 %
Aurinia Pharmaceuticals Inc   56.37 %
Pulmatrix Inc   53.09 %
Novavax inc   51.88 %
Gsk Plc  51.22 %
Q32 Bio Inc   50.33 %
Idexx Laboratories Inc  48.69 %

Date modified: 2026-09-18T13:11:06+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.